<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4288723</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P69</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P69</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Ferris</surname><given-names>Robert L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Cohen</surname><given-names>Ezra</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Gash</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Whiting</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Manjarrez</surname><given-names>Kristi</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Dietsch</surname><given-names>Greg</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Hershberg</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Bryan</surname><given-names>James Kyle</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</aff><aff id="I2"><label>2</label>UC San Diego Health System - La Jolla, La Jolla, Ca, USA</aff><aff id="I3"><label>3</label>VentiRx Pharmaceuticals, Seattle, WA, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P69</fpage><lpage>P69</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Ferris et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Ferris et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P69"/><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec><title>Background</title><p>Recurrent or metastatic SCCHN has few effective therapeutic options. In these patients, the EXTREME regimen added Cetuximab--an EGFR-specific monoclonal antibody--to a regimen of Platinum/5-FU and improved median overall survival (OS) by 2.7 months and progression-free survival (PFS) by 2.3 months [<xref ref-type="bibr" rid="B1">1</xref>]. Given the natural killer (NK) cell-mediated antibody dependent cellular cytotoxicity (ADCC) of Cetuximab-mediated tumor killing and the immunogenic antitumor effects of chemotherapeutics like Platinum and 5-FU, synergy with immunotherapy may be one option to further improve outcomes.</p><p>VTX-2337 (Motolimod), a novel Toll-like receptor 8 (TLR8) agonist, stimulates myeloid dendritic cells (mDC), monocytes, and NK cells. Preclinical data have demonstrated increased ADCC with IgG1 monoclonal antibodies when Motolimod is added [<xref ref-type="bibr" rid="B2">2</xref>] as well as synergistic effects when Motolimod is combined with chemotherapy [<xref ref-type="bibr" rid="B3">3</xref>]. A Phase Ib study of Cetuximab and Motolimod in patients with Platinum-refractory or -intolerant recurrent or metastatic SCCHN has shown the combination to be both tolerable and active in this setting [<xref ref-type="bibr" rid="B4">4</xref>]. Translational medicine correlates demonstrated TLR8 activation and enhanced NK cell mobilization and activation. There is strong rationale to further assess the safety, tolerability, and efficacy of this combination in SCCHN patients. A large trial in this population will allow exploration of a number of translational medicine correlates to illuminate the combination of immunotherapy with other anti-cancer therapies.</p></sec><sec sec-type="methods"><title>Methods</title><p>This randomized, double-blind, placebo-controlled, Phase II study evaluates the safety and efficacy of Motolimod with EXTREME vs. EXTREME alone for first-line treatment of recurrent or metastatic SCCHN. Patients must have a confirmed diagnosis, measurable disease, and no prior systemic therapy for their recurrent or metastatic disease. Approximately 175 patients will be randomized 1:1 to receive Motolimod or placebo + EXTREME for 6 cycles (q3wk), followed by weekly Cetuximab with biweekly Motolimod/placebo. The primary objective is to compare PFS according to immune-related response evaluation criteria between the two treatment arms, as determined by independent review. Secondary objectives include comparisons of safety and OS between the two treatment groups.</p><p>Translational studies will be conducted to compare immune biomarker response by a multiplexed panel of cytokines, chemokines, and inflammatory markers; genetic polymorphisms that may impact response to a TLR8 agonist or to Cetuximab; and the effect of immune cell subsets within the tumor on response to treatment and/or clinical outcome between the two treatment groups. Pharmacokinetics of Motolimod will also be evaluated. Enrollment began in October 2013. (NCT01836029)</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><name><surname>Vermorken</surname><given-names>JB</given-names></name><name><surname>Mesia</surname><given-names>R</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><etal/><article-title>Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer</article-title><source>N Engl J Med</source><year>2008</year><fpage>1116</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">18784101</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Stephenson</surname><given-names>RM</given-names></name><name><surname>Lim</surname><given-names>CL</given-names></name><name><surname>Matthews</surname><given-names>M</given-names></name><etal/><article-title>TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells</article-title><source>Cancer Immunol Immunother</source><year>2013</year><volume>62</volume><issue>8</issue><fpage>1347</fpage><lpage>57</lpage><comment>Aug</comment><pub-id pub-id-type="doi">10.1007/s00262-013-1437-3</pub-id><pub-id pub-id-type="pmid">23685782</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="book"><name><surname>Monk</surname><given-names>B</given-names></name><name><surname>Brady</surname><given-names>M</given-names></name><name><surname>Lankes</surname><given-names>H</given-names></name><etal/><article-title>VTX-2337, a TLR8 Agonist, Plus Chemotherapy in Recurrent Ovarian Cancer: Preclinical and Phase 1 Data by the Gynecology Oncology Group</article-title><source>American Society of Clinical Oncology Annual Meeting</source><year>2013</year><publisher-name>June 3-7, Chicago, IL, USA</publisher-name></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Chow</surname><given-names>L</given-names></name><name><surname>Eaton</surname><given-names>K</given-names></name><name><surname>Baik</surname><given-names>C</given-names></name><etal/><article-title>Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>88</volume><fpage>503</fpage><lpage>504</lpage></mixed-citation></ref></ref-list></back></article>